Presented at ASCO 2025, new post-hoc analyses from the Phase III ARANOTE trial showed that darolutamide (Nubeqa) plus ADT ...

The results from ATOMIC trial, presented at ASCO 2025, show that adding atezolizumab (Tecentriq) to FOLFOX chemotherapy ...

Zai Lab presented updated Phase 1 data for ZL-1310, an investigational DLL3-targeted antibody-drug conjugate (ADC) for ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

The new data from the PERSEUS and CEPHEUS studies show that Darzalex Faspro®-based regimens achieve up to 95% 4-year PFS and ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...

The FDA approved darolutamide (Nubeqa®) for metastatic castration-sensitive prostate cancer, based on the Phase III ARANOTE ...

Xcelerate has unveiled the bioX Genetics Platform, which cuts the time needed to detect genetic variants by 98% and achieves ...

The Phase 3 AMPLITUDE trial showed that adding niraparib to abiraterone acetate and prednisone reduced radiographic ...

A Canadian Cancer Society-funded trial shows a 3-year structured exercise program post-chemotherapy improves survival for colon cancer patients. Involving 889 participants, the trial saw a 28% ...